Foundation Medicine has partnered with Repare Therapeutics to offer genomic profiling for patients participating in Repare's ongoing MYTHIC study involving the Lunresertib drug.
The collaboration aims to use FoundationOneCDx, a comprehensive genomic profiling test, as a potential companion diagnostic for the Lunresertib program. Lunresertib is currently being assessed individually and in combination in several studies across Europe and North America. The partnership seeks to use and advance diagnostics in cancer treatment, especially in cases with complex biomarkers and high unmet needs.
Foundation Medicine specializes in comprehensive genomic profiling for cancer treatment. The company provides clinical diagnostic tests that analyze cancer’s genetic alterations, enabling personalized treatment plans. Its key products include FoundationOneCDx, FoundationOneLiquid CDx for blood-based cancers, and FoundationOneHeme for hematologic malignancies.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.